Acute Repetitive Seizures Market (2026 - 2033)

Acute Repetitive Seizures Market Summary

The global acute repetitive seizures market was valued at USD 3.6 billion in 2025 and is projected to grow from USD 4.0 billion in 2026 to USD 9.3 billion in 2033, at a CAGR of 12.8% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 40.0% in 2025. The global market is driven by the healthcare providers that increasingly seek reliable treatments, thus continuously increasing the incentive for pharmaceutical advancements in this area. The rising prevalence of neurological disorders, particularly epilepsy, is another significant driver contributing to the market growth.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

According to the World Health Organization (WHO) fact sheet 2024, epilepsy is a neurological condition affecting about 50 million people worldwide. Many existing therapies fail to provide adequate control of acute repetitive seizures and may come with undesirable adverse effects. This gap in effective treatment solutions prompts pharmaceutical companies to prioritize innovation and the development of novel therapeutic options that can better serve patient requirements.

Approximately 50 million people globally are affected by epilepsy, which underscores a substantial patient population in urgent need of effective management strategies. This rising incidence not only heightens demand for treatment options but also encourages healthcare stakeholders to invest in therapies that can significantly improve the quality of life for those affected by these conditions.

Moreover, advancements in the product pipeline are crucial for market expansion. Ongoing research and development efforts are yielding new drug approvals and innovative treatment modalities, which are essential for enhancing patient outcomes. As more effective therapies become available, the overall demand for treatments targeting acute repetitive seizures is expected to rise, driving further market growth. The integration of innovative solutions in clinical settings reinforces the importance of continued investment in research to address existing treatment shortfalls.

An increase in awareness of seizure management and proactive healthcare initiatives is facilitating better diagnosis and treatment, particularly in emerging markets. The growing trend towards outpatient care, such as home healthcare and telemedicine, further enhances patient accessibility while reducing hospitalization costs. Combined with increased investment in neurology research, primarily in regions such as North America and Europe, these key factors create a conducive environment for the industry to thrive in the forthcoming years.

Analyst Perspective

The market is expanding as awareness of seizure emergencies and the need for rapid intervention continues to rise. Growing adoption of rescue therapies, improved access to epilepsy care, and advances in intranasal and other easy-to-administer drug formulations are transforming the management of seizure clusters outside hospital settings. Healthcare providers are placing greater emphasis on early treatment to reduce ER visits, prevent complications, and improve patient quality of life. Companies with strong neurology portfolios, innovative drug-delivery technologies, and robust clinical development capabilities are expected to strengthen their market positions. Market growth is expected to depend on continued therapeutic innovation, increasing patient access, favorable reimbursement, and convenient, fast-acting, and safe delivery of rescue treatments for seizure emergencies.

Product Insights

The diastat rectal gel segment dominated the market in 2025. Its leadership is attributed to its long-standing clinical use, established efficacy in managing seizure clusters, broad physician familiarity, and widespread availability across major healthcare markets. Despite the growing adoption of intranasal rescue therapies, Diastat Rectal Gel continues to hold a significant market share due to its proven therapeutic effectiveness, established reimbursement coverage, and extensive patient base built over years of clinical use. However, its share is expected to gradually decline over the forecast period as more convenient intranasal formulations gain wider acceptance.

The USL-261 segment is expected to witness the fastest CAGR over the forecast period, owing to its effectiveness as an intranasal treatment for rapid seizure control. Its user-friendly administration and favorable safety profile position are the preferred option among healthcare providers, effectively addressing significant unmet clinical needs in the management of acute seizures.

Regional Insights

The acute repetitive seizures industry in North America dominated the global market with a revenue share of over 40.0% in 2025. Market growth in the region is driven by a high prevalence of epilepsy and neurological disorders, complemented by a robust healthcare infrastructure. Significant investments in research and development, along with a favorable regulatory environment and access to advanced treatment options, reinforce the region's dominance, attracting both patients and pharmaceutical companies.

To learn more about this report, Download Free Sample Report

U.S. Acute Repetitive Seizures Market Trends

The acute repetitive seizures industry in the U.S. dominated the North America market with the largest revenue share in 2025. Elevated healthcare expenditures, the presence of leading pharmaceutical companies, and ongoing advancements in drug development collectively enhance accessibility to treatments. Furthermore, increased awareness and improved diagnostic capabilities significantly contribute to the market's expansion in the U.S.

Europe Acute Repetitive Seizures Market Trends

The acute repetitive seizures industry in Europe held a substantial market share in 2025 due to rising investments in neurology research and an emphasis on innovative treatment solutions. Strong government support for healthcare initiatives, heightened awareness of seizure management, and increased demand for effective medications facilitate advances in therapeutic options.

The Germany acute repetitive seizures industry is expected to grow over the forecast period. The nation's commitment to advancing neurology treatments, combined with a high prevalence of epilepsy, fosters strong demand for effective therapies. Germany’s regulatory environment further supports rapid drug approvals, significantly bolstering market growth and innovation.

Asia Pacific Acute Repetitive Seizures Market

The acute repetitive seizures industry in Asia Pacific is expected to register the fastest CAGR over the forecast period, supported by a rising incidence of neurological disorders and increased awareness of epilepsy treatment options. Developing healthcare infrastructure and growing investments in medical research and development position the region for substantial growth as patient-centric care becomes increasingly prioritized.

The Japan acute repetitive seizures industry dominated the Asia Pacific market in 2025. The aging population, coupled with rising awareness of neurological disorders, stimulates demand for effective therapies. Furthermore, Japan’s commitment to research and development significantly enhances its competitive position within the region.

Key Acute Repetitive Seizures Company Insights

Some key companies operating in the market include UCB S.A. (Belgium); Neurelis, Inc.; Bausch Health Companies Inc.; Grupo Ferrer Internacional, S.A.; and SERB. Strategic initiatives emphasize significant R&D investments in innovative therapies, partnerships with healthcare providers to improve distribution, and marketing efforts to boost patient awareness and access to treatments.

• Neurelis, Inc. is a biotechnology firm dedicated to creating pioneering therapies for epilepsy and central nervous system disorders. Their primary offering, VALTOCO, is an FDA-approved intranasal diazepam spray for managing intermittent seizures in individuals aged six and over.
• Grupo Ferrer Internacional, S.A., a pharmaceutical company, specializes in developing and marketing a range of healthcare products, particularly for neurological disorders. They emphasize innovative formulations and delivery systems in the industry to enhance treatment efficacy and patient compliance.

Key Acute Repetitive Seizures Companies

The following key companies have been profiled for this study on the acute repetitive seizures market:

• UCB S.A., Belgium

• Neurelis, Inc.

• Bausch Health Companies Inc.

• Grupo Ferrer Internacional, S.A.

• SERB

Recent Developments

• In April 2025, Neurelis received U.S. FDA approval for VALTOCO (diazepam nasal spray) for the immediate treatment of seizure clusters in children aged 2–5 years, expanding access to intranasal rescue therapy for pediatric patients.

• In April 2025, Aquestive Therapeutics received U.S. FDA approval for Libervant Buccal Film, the first orally administered rescue therapy for seizure clusters in children aged 2–5 years, broadening treatment options for pediatric acute repetitive seizures.

• In December 2024, Neurelis presented new clinical findings on VALTOCO and seizure cluster management at the American Epilepsy Society Annual Meeting, reinforcing evidence supporting immediate-use rescue therapies for acute repetitive seizures.

Global Acute Repetitive Seizures Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global acute repetitive seizures market report based on product and region:

• Product Outlook (Revenue, USD Billion, 2021-2033)
  • USL-261
  • NRL-1
  • AZ-002
  • Diastat Rectal Gel
  • Others
• Regional Outlook (Revenue, USD Billion, 2021-2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Sweden
    • Norway
    • Denmark
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • Thailand
    • South Korea
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa
    • Saudi Arabia
    • South Africa
    • UAE
    • Kuwait